From the strategic update in March 2021.
Personally, I'm very interested to see if Bisantrene inhibits FTO in non-cancerous cells and how that effects the downstream expression of genes and the impact that has on cellular function, because there have been a couple non-cancerous diseases linked to overexpression of FTO. I don't know how much 'low-cost' is, but I believe the cost to reward ratio is worth taking a look at.
Ann: Race Initiates Heart Safety Preclinical Study for Bisantrene, page-36
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.50 |
Change
-0.020(1.32%) |
Mkt cap ! $258.9M | |||
| Open | High | Low | Value | Volume |
| $1.53 | $1.55 | $1.50 | $75.48K | 50.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12000 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.50 | 3500 | 1 |
View Market Depth
| Last trade - 12.36pm 20/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |